279 related articles for article (PubMed ID: 24170546)
1. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Dunne PD; McArt DG; Blayney JK; Kalimutho M; Greer S; Wang T; Srivastava S; Ong CW; Arthur K; Loughrey M; Redmond K; Longley DB; Salto-Tellez M; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2014 Jan; 20(1):164-75. PubMed ID: 24170546
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.
Ciardiello D; Blauensteiner B; Matrone N; Belli V; Mohr T; Vitiello PP; Martini G; Poliero L; Cardone C; Napolitano S; De Falco V; Giunta EF; Ciaramella V; Corte CD; Barra G; Selvaggi F; Franco R; Marino FZ; Cuomo A; Morgillo F; Troiani T; Sibilia M; Ciardiello F; Martinelli E
Med Oncol; 2021 Feb; 38(3):24. PubMed ID: 33570712
[TBL] [Abstract][Full Text] [Related]
3. EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.
Dunne PD; Dasgupta S; Blayney JK; McArt DG; Redmond KL; Weir JA; Bradley CA; Sasazuki T; Shirasawa S; Wang T; Srivastava S; Ong CW; Arthur K; Salto-Tellez M; Wilson RH; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2016 Jan; 22(1):230-242. PubMed ID: 26283684
[TBL] [Abstract][Full Text] [Related]
4. Axl Is a Potential Cancer Prognostic Marker for the Migration and Invasion of Nasopharyngeal Carcinoma.
Jiang C; Zhou L; Wang H; Zhang Q; Xu Y
Adv Clin Exp Med; 2016; 25(3):531-7. PubMed ID: 27629742
[TBL] [Abstract][Full Text] [Related]
5. Axl is a prognostic marker in oral squamous cell carcinoma.
Lee CH; Yen CY; Liu SY; Chen CK; Chiang CF; Shiah SG; Chen PH; Shieh YS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S500-8. PubMed ID: 21842265
[TBL] [Abstract][Full Text] [Related]
6. Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma.
Li Y; Jia L; Ren D; Liu C; Gong Y; Wang N; Zhang X; Zhao Y
IUBMB Life; 2014 Jul; 66(7):507-18. PubMed ID: 24984960
[TBL] [Abstract][Full Text] [Related]
7. Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
Abdel-Rahman WM; Al-Khayyal NA; Nair VA; Aravind SR; Saber-Ayad M
World J Gastroenterol; 2017 May; 23(19):3440-3448. PubMed ID: 28596680
[TBL] [Abstract][Full Text] [Related]
8. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion.
Yen SY; Chen SR; Hsieh J; Li YS; Chuang SE; Chuang HM; Huang MH; Lin SZ; Harn HJ; Chiou TW
Oncogene; 2016 Apr; 35(17):2156-65. PubMed ID: 26257061
[TBL] [Abstract][Full Text] [Related]
10. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
Seike M; Kim CH; Zou F; Noro R; Chiba M; Ishikawa A; Κunugi S; Kubota K; Gemma A
Oncol Rep; 2017 Jun; 37(6):3261-3269. PubMed ID: 28440492
[TBL] [Abstract][Full Text] [Related]
11. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer.
Cardone C; Blauensteiner B; Moreno-Viedma V; Martini G; Simeon V; Vitiello PP; Ciardiello D; Belli V; Matrone N; Troiani T; Morgillo F; Zito Marino F; Dentice M; Nappi A; Boccaccino A; Antoniotti C; Cremolini C; Pietrantonio F; Prager GW; Normanno N; Maiello E; Argiles G; Elez E; Signoriello G; Franco R; Falcone A; Tabernero J; Sibilia M; Ciardiello F; Martinelli E
Eur J Cancer; 2020 Oct; 138():1-10. PubMed ID: 32818762
[TBL] [Abstract][Full Text] [Related]
12. AXL is an oncotarget in human colorectal cancer.
Martinelli E; Martini G; Cardone C; Troiani T; Liguori G; Vitagliano D; Napolitano S; Morgillo F; Rinaldi B; Melillo RM; Liotti F; Nappi A; Bianco R; Berrino L; Ciuffreda LP; Ciardiello D; Iaffaioli V; Botti G; Ferraiolo F; Ciardiello F
Oncotarget; 2015 Sep; 6(27):23281-96. PubMed ID: 25966280
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
14. AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.
Falcone I; Conciatori F; Bazzichetto C; Bria E; Carbognin L; Malaguti P; Ferretti G; Cognetti F; Milella M; Ciuffreda L
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182542
[TBL] [Abstract][Full Text] [Related]
15. YES-associated protein 1 promotes adenocarcinoma growth and metastasis through activation of the receptor tyrosine kinase Axl.
Cui ZL; Han FF; Peng XH; Chen X; Luan CY; Han RC; Xu WG; Guo XJ
Int J Immunopathol Pharmacol; 2012; 25(4):989-1001. PubMed ID: 23298489
[TBL] [Abstract][Full Text] [Related]
16. The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.
Hsieh MS; Yang PW; Wong LF; Lee JM
Oncotarget; 2016 Jun; 7(24):36956-36970. PubMed ID: 27172793
[TBL] [Abstract][Full Text] [Related]
17. TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.
Schmitz R; Valls AF; Yerbes R; von Richter S; Kahlert C; Loges S; Weitz J; Schneider M; Ruiz de Almodovar C; Ulrich A; Schmidt T
Oncotarget; 2016 Aug; 7(35):56355-56370. PubMed ID: 27486820
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.
Song X; Wang H; Logsdon CD; Rashid A; Fleming JB; Abbruzzese JL; Gomez HF; Evans DB; Wang H
Cancer; 2011 Feb; 117(4):734-43. PubMed ID: 20922806
[TBL] [Abstract][Full Text] [Related]
19. Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma.
Reichl P; Dengler M; van Zijl F; Huber H; Führlinger G; Reichel C; Sieghart W; Peck-Radosavljevic M; Grubinger M; Mikulits W
Hepatology; 2015 Mar; 61(3):930-41. PubMed ID: 25251599
[TBL] [Abstract][Full Text] [Related]
20. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
